# ET-1, MMPs, ZAG, and APN Link Reduced Ocular Perfusion to Glaucoma

**Authors:** Maren Kasper, Kai Rothaus, Lasse Schopmeyer, Dirk Bauer, Swaantje Grisanti, Carsten Heinz, Karin Loser, Claudia Lommatzsch

PMC · DOI: 10.3390/biom15101364 · 2025-09-25

## TL;DR

This study links specific proteins and peptides to reduced blood flow in the eye, which is associated with glaucoma.

## Contribution

The study identifies ET-1, APN, MMP-3, ZAG, and other proteins as potential biomarkers for impaired ocular perfusion in glaucoma.

## Key findings

- Glaucomatous eyes show reduced retinal nerve fiber layer thickness and vessel density.
- Elevated levels of ET-1, MMP-3, ZAG, and APN in aqueous humor correlate with impaired ocular perfusion.
- Multivariable analysis confirms a link between APN levels and reduced vessel density in glaucoma.

## Abstract

Purpose: This study sets out to analyze the correlation of ET-1, a vasoactive peptide, along with various cytokines and vascular factors, with clinical parameters and OCT/OCT-A measurements in glaucoma participants. Methods: Eyes of participants with cataract (n = 30) or glaucoma (n = 87) were examined with optical coherence tomography (OCT) and OCT angiography (OCT-A). Aqueous humor (AqH) from the examined eye and plasma were sampled during cataract or glaucoma surgery and analyzed by means of ELISA and Luminex assay to determine their levels of ET-1 and 35 proteins deemed relevant for regulation of the AqH outflow pathway, ocular perfusion (OP), and glucose metabolism. Results: Glaucomatous eyes are characterized by reductions in RNFL thickness and OP, reflected by reduced vessel density. Furthermore, significantly elevated peripheral ET-1 levels were detected in participants with glaucoma. In addition, significantly elevated AqH levels of MMP-2, MMP-3, ET-1, sEMMPRIN, ZAG, sLOX-1, follistatin, cortisol, endostatin, sTIE-2, and PDGF-BB were detected in the glaucomatous eyes, with correlation to reduced VD for APN, C3a, MMP-3, resistin, sTIE-2, and ZAG. Multivariable analysis showed a correlation of AqH APN levels with the reduced VD in glaucomatous eyes. Conclusions: The peripheral ET-1 level and the intraocular levels of APN, C3a, MMP-3, resistin, sTIE-2, and ZAG are associated with impaired OP in glaucoma. Furthermore, elevated intraocular levels of MMP-3, ZAG, and APN were identified as biomarkers for impaired perfusion in glaucoma.

## Linked entities

- **Proteins:** EDN1 (endothelin 1), MMP2 (matrix metallopeptidase 2), MMP3 (matrix metallopeptidase 3), AZGP1 (alpha-2-glycoprotein 1, zinc-binding), OLR1 (oxidized low density lipoprotein receptor 1), LOC5564573 (agrin), pdgfbb (platelet derived growth factor subunit Bb), C3 (complement C3), LOC114022543 (uncharacterized LOC114022543), ANPEP (alanyl aminopeptidase, membrane)
- **Diseases:** glaucoma (MONDO:0005041), cataract (MONDO:0005129)

## Full-text entities

- **Genes:** MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, RETN (resistin) [NCBI Gene 56729] {aka ADSF, FIZZ3, RENT, RETN1, RSTN, XCP1}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, EDN1 (endothelin 1) [NCBI Gene 1906] {aka ARCND3, ET1, HDLCQ7, PPET1, QME}, FST (follistatin) [NCBI Gene 10468] {aka FS}, ANPEP (alanyl aminopeptidase, membrane) [NCBI Gene 290] {aka AP-M, AP-N, APN, CD13, GP150, LAP1}, COL18A1 (collagen type XVIII alpha 1 chain) [NCBI Gene 80781] {aka GLCC, KNO, KNO1, KS}, OLR1 (oxidized low density lipoprotein receptor 1) [NCBI Gene 4973] {aka CLEC8A, LOX1, LOXIN, SCARE1, SLOX1}, C3 (complement C3) [NCBI Gene 718] {aka AHUS5, ARMD9, ASP, C3a, C3b, CPAMD1}, AZGP1 (alpha-2-glycoprotein 1, zinc-binding) [NCBI Gene 563] {aka ZA2G, ZAG}
- **Diseases:** Glaucomatous eyes (MESH:D005134), cataract (MESH:D002386), impaired OP (MESH:D015817), Glaucoma (MESH:D005901)
- **Chemicals:** cortisol (MESH:D006854), glucose (MESH:D005947)

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12562824/full.md

---
Source: https://tomesphere.com/paper/PMC12562824